Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 12/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.67 |
| ▸ | MAPK6 | Q16659 | 4/20 | 0.67 |
| ▸ | MAPKAPK3 | Q16644 | 3/20 | 0.67 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.67 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.67 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | TTK | P33981 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.48 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.48 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.46 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27750633 | 0.99 | MAP2K4 (0.65) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL5372294 | 0.89 | MAP2K4 (0.57) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL5383004 | 0.87 | MAP2K4 (0.68) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL2862381 | 0.87 | MAP2K4 (0.70) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL5378360 | 0.87 | MAP2K4 (0.61) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL8437332 | 0.86 | MAP2K4 (0.84) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL5801309 | 0.86 | MAP2K4 (0.67) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL5377211 | 0.86 | MAP2K4 (0.57) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL9987358 | 0.85 | MAPK1 (0.66) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL5377479 | 0.85 | MAPK1 (0.53) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725694-B2 | Composition for collecting and preserving placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-08-08 | — | — | US | claimed |
| US-9598669-B2 | Composition for collecting placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-03-21 | — | — | US | claimed |
| US-20100291679-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION | 2010-11-18 | — | — | US | claimed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | claimed |
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SINGNAL PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | claimed |
| US-20170327788-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION (US) | 2017-11-16 | — | — | US | disclosed |
| US-9725694-B2 | Composition for collecting and preserving placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| US-9598669-B2 | Composition for collecting placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
| CN-101374941-A | Improved composition for collecting and preserving placental stem cells and methods of using the composition | ANTHROGENESIS CORP (US) | 2009-02-25 | — | — | CN | disclosed |
| WO-2008091925-A2 | TREATMENT OF AORTIC DISSECTION OR ANEURYSM | COOK INCORPORATED (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008091925-A2 | TREATMENT OF AORTIC DISSECTION OR ANEURYSM | COOK INCORPORATED (US) | 2008-07-31 | — | — | WO | disclosed |
| EP-1827422-A2 | JNK INHIBITORS FOR THE TREATMENT OF CNS INJURY | CELGENE CORPORATION (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2003102151-A2 | MODULATING CELL DIFFERENTIATION AND TREATING MYELOPROLIFERTIVE DISORDERS WITH JNK/MKK INHIBITORS | CELGENE CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003099221-A2 | METHODS FOR USING JNK INHIBITORS FOR TREATING OR PREVENTING DISEASE-RELATED WASTING | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-1313711-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAP2K4 71/4885MAPK1 16/4885MAPK6 31/4885 |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAP2K4 58/4885MAPK1 22/4885MAPK6 33/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAP2K4 71/4885MAPK1 16/4885MAPK6 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.